ACE inhibitors and AT1 receptor antagonists: Is two better than one?  by Noris, Marina & Remuzzi, Giuseppe
Kidney International, Vol. 61 (2002), pp. 1545–1547
EDITORIAL
ACE inhibitors and AT1 receptor antagonists:
Is two better than one?
In clinical trials, pharmacological inhibition of the for ACE, the ACE inhibitor may not completely block
Ang II formation, whereas increases in Ang II levelsrenin-angiotensin system (RAS) with angiotensin-con-
verting enzyme (ACE) inhibitors slow the progression may compete with the AT1 receptor blocker at the recep-
tor site. For this reason it has been suggested that anof renal disease to end-stage renal failure, thus attesting
the central role of angiotensin II (Ang II) in the patho- ACE inhibitor/AT1 receptor antagonist combination may
offer a better therapeutic effect than treatment with ei-physiology of chronic renal injury. The development of
orally active Ang II subtype 1 (AT1) receptor antagonists ther agent alone. In fact, in rats with renal ablation [4]
and in rats with passive Heymann nephritis (abstract;has provided an alternative system of inhibiting the RAS,
thereby creating a novel potential therapy for chronic Zoja C et al, J Am Soc Nephrol 12:830A, 2001), the com-
bination of ACE inhibitors and AT1 receptor antagonistrenal diseases. AT1 receptor antagonists differ from ACE
inhibitors in the effects on the RAS and on bradykinin induced a greater renal protection than either treatment
alone. Data on the use of combination of ACE inhibitormetabolism. Elevations in bradykinin levels by ACE in-
hibitors and stimulation of angiotensin subtype 2 re- and AT1 receptor antagonist therapy in humans are few.
In 12 sodium-depleted normal subjects a greater reduc-ceptors resulting from AT1 receptor antagonists may pro-
duce therapeutic effects unique to each class of drug. tion in blood pressure and greater increases in plasma
renin activity were observed after the addition of theNevertheless, in animal models of chronic renal disease,
ACE inhibitors and AT1 receptor antagonists exert equiv- AT1 receptor antagonist losartan to enalapril treatment
than after doubling the dose of enalapril, suggesting thatalent renoprotection, implying that their renoprotective
effects result primarily from inhibition of Ang II-medi- the combination resulted in more effective inhibition of
the RAS [4]. In 11 patients with chronic renal diseaseated stimulation of angiotensin subtype 1 receptors. In
Fawn-hooded hypertensive rats [1], a model of geneti- of various etiologies, the addition of an AT1 receptor
cally determined hypertension and progressive renal in- antagonist to ACE inhibitor therapy induced a further
jury, and in rats with passive Heymann nephritis [2], a 30% reduction in proteinuria and no change in creatinine
model of human membranous glomerulopathy, treat- clearance after 2 weeks of combined treatment [5].
ment with an ACE inhibitor or with an AT1 receptor an- In this issue of Kidney International, Delles et al com-
tagonist lowered blood pressure and glomerular capil- pared in a randomized, crossover study the effect of 1-week
lary pressure to a similar degree and afforded equivalent treatment with an ACE inhibitor, enalapril, an AT1 re-
renal protection. Clinical data comparing ACE inhibitor ceptor antagonist, eprosartan, and their combination on
and AT1 receptor antagonist therapy in renal disease are renal hemodynamics in human essential hypertension [6].
limited to short-term studies, which indicate that AT1 Neither drug alone had a clear-cut effect on renal plasma
receptor antagonists have equivalent effects to ACE in- flow over the observation period, whereas an increase in
hibitors on the major determinants of renal disease pro- RPF was found with combination therapy. Renal vascu-
gression, specifically blood pressure and proteinuria. In lar resistance was reduced by each treatment alone, how-
hypertensive patients with renal impairment, the AT1 ever, the most prominent effect was observed with the
receptor antagonist, candesartan, exerted a renal vaso- combination therapy. Glomerular filtration rate (GFR)
dilator effect similar to that observed during treatment was not affected by any treatment. Of note, the effects
with the ACE inhibitor, enalapril [3]. Some concerns have of enalapril, eprosartan, and combination therapy on re-
been raised about the completeness of the RAS blockade nal hemodynamics were independent of blood pressure
achieved by either ACE inhibitors or AT1 receptor an- changes, as documented by the lack of significant corre-
tagonists. Because enzymes, as chymase, can substitute lations between blood pressure changes and changes in
renal plasma flow. These findings are consistent with pre-
vious work by other investigators who found additive ef-
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bination therapy on cardiac output and ejection fractionoxide.
in patients with heart failure and on proteinuria in pa-
tients with nephropathy, which were independent of 2002 by the International Society of Nephrology
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blood pressure [7]. Following this line of investigation, by pretreatment with a selective B2 kinin receptor antag-
onist. In normotensive subjects, a single oral dose of en-preliminary data in patients with chronic nephropathies
document that doses of ACE inhibitors and AT1 receptor alapril significantly increased the nitric oxide release rate
from the lung, as evaluated by measuring nitric oxideantagonist higher than the maximum recommended doses
for blood pressure control further reduced urinary pro- concentration in the exhaled air, however, the same treat-
ment had no effect on nitric oxide production in hyper-tein excretion as compared to conventional doses, with-
out significant changes in blood pressure (abstract; Wein- tensive patients [8]. ACE inhibitors, besides stimulating
nitric oxide synthesis, also induced the expression of theberg SM et al, J Am Soc Nephrol 11:79A, 2000).
However, one must be cautious in assuming that the endothelial constitutive isoform of nitric oxide synthase
(ecNOS), as documented by increased ecNOS expres-renal effects of ACE inhibitors and AT1 receptor antago-
nist and their combination are independent of systemic sion in cultured bovine aortic endothelial cells incubated
with ramiprilat, and by increased miocardial ecNOS ex-hemodynamics, as several important limitations make
the study by Delles et al [6] far from conclusive. First, pression in deoxycorticosterone acetate (DOCA)-salt
hypertensive rats treated with the ACE inhibitor, qui-it is likely that 1-week therapy is not long enough to
fully disclose the systemic and renal effects of ACE in- nalapril, as compared with rats receiving vehicle [9]. Fi-
nally, ACE inhibitors exert an antioxidant action andhibitors and AT1 receptor antagonists. It should be noted
that the maximum antihypertensive effect of both ACE increase the activity of endothelial superoxide dismutase
(ecSOD) in arterial vessels, which may prevent nitricinhibitors and AT1 receptor antagonists may be observed
after at least 6 weeks of therapy [4]. Thus, an assessment oxide degradation by reactive oxygen species. AT1 recep-
tor antagonist have been shown to stimulate nitric oxideof the full response to treatment should be delayed until
after 6 weeks. In a previous study in which 20 patients production and activity as well. Comparative studies in
DOCA-salt hypertensive rats, in patients with coronarywith essential hypertension and normal serum creatinine
concentrations were randomized to receive either enala- artery disease [10], and in healthy subjects documented
that ACE inhibitors and AT1 receptor antagonists hadpril or the AT1 receptor antagonist, irbesartan, for 12
weeks, both treatments were equally effective in low- the same stimulating effects on nitric oxide synthesis,
ecNOS, and ecSOD expression in vascular endothelium.ering mean blood pressure and both resulted in decreases
in renal vascular resistance and increases in RPF with AT1 receptor antagonists, on the other hand, have no
effect on bradykinin levels. However, blockade of AT1no average change in GFR [4].
Another limitation of the study by Delles et al [6] is receptors in the presence of elevated Ang II levels results
in stimulation of subtype 2 (AT2) receptors that arethat their patients were not kept on a control of sodium
intake during the study period. This is a crucial point known to mediate Ang II-induced production of nitric
oxide. In a rat model of cardiac failure, the importancesince it is well-known that oral salt intake considerably
influences renal hemodynamics and renal response to of AT2 receptor stimulation has been demonstrated by
the observation that administration of an AT2 receptorRAS inhibition. During low, but not high, sodium intake,
activation of the intrarenal RAS system occurs that may antagonist blocks the cardioprotective effect of AT1 re-
ceptor antagonist.potentiate the efficacy of ACE inhibitors. In patients
with chronic nephropathies, treatment with the ACE Thus, combined administration of ACE inhibitors and
AT1 receptor antagonist, by indirect nitric oxide syn-inhibitor, lisinopril, associated with a low-salt diet, pro-
vided a higher renoprotective effect than the same ACE thesis stimulation via bradykinin and by direct nitric
oxide synthesis stimulation via the AT2 receptors, mayinhibitor but with a high-salt diet.
Delles et al [6] also investigated the mechamisms by exert a synergistic effect on endothelial-dependent vaso-
dilatation.which enalapril and eprosartan influence renal hemody-
namics in essential hypertension, moving from the hy- However, very little data are available in vivo in hu-
man subjects on the effects of the two classes of drugspothesis that drug association may improve the function
of renal vascular endothelium, particularly its capacity on renal vascular nitric oxide.
In their report Delles et al [6] examined the effectto produce the potent vasodilator nitric oxide.
There are a number of mechanisms by which ACE of L-NMMA, a competitive inhibitor of nitric oxide syn-
thase, on renal hemodynamic parameters. They foundinhibitors and AT1 receptor antagonists augment nitric
oxide activity. ACE, also termed kininase II, is respon- that in patients with essential hypertension, adminis-
tration of L-NMMA decreased RPF by approximatelysible for the breakdown of bradykinin, which is a po-
tent stimulator of nitric oxide synthase. ACE inhibition, the same percentage independent of whether they were
taking placebo, enalapril, eprosartan, or their combina-therefore, results in elevated bradykinin levels and in-
creased nitric oxide synthesis. Incubation of human cul- tion. These results at first glance rule out any change
in renal endothelial nitric oxide production induced bytured endothelial cells with the ACE inhibitor, ramipri-
lat, increased nitric oxide formation, which was prevented enalapril, eprosartan, or their combination. However, to
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authors calculated correlation coefficients between the in-
crease in RPF induced by enalapril, eprosartan, or the
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